Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ACGX NEWS! Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024 https://finance.yahoo.com/news/alliance-creative-group-acgx-releases-123000832.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance @ACGpaul
$GNPX NEWS! @Genprex dosing subjects in trial of combination therapy for small-cell lung cancer
GlobalData
Wed, May 15, 2024, 4:42 AM EDT
In this article:
GNPX
+7.53%
US-based gene therapy company Genprex has enrolled and dosed the first subject in a Phase I/II trial to assess a combination therapy for extensive-stage small cell lung cancer (ES-SCLC).
The Acclaim-3 trial aims to determine the safety and optimal dosage of Reqorsa (quaratusugene ozeplasmid) Immunogene Therapy when given in combination with Genentech’s Tecentriq.
The open-label dose escalation and clinical response study is enrolling patients who have not experienced tumor progression following initial treatment with Tecentriq and chemotherapy.
Its first phase aims to enroll up to 12 subjects across roughly ten clinical sites in the US to identify the maximum tolerated dose.
Should the Phase I study proceed without dose-limiting toxicities, the highest dose tested will be the recommended Phase II dose.
The Phase II portion is anticipated to involve around 50 patients at up to 15 US locations.
Treatment with Reqorsa and Tecentriq will continue until disease progression or unacceptable toxicity occurs.
Genprex plans to begin the Phase II expansion study in the second half of this year.
A futility analysis is scheduled for after the 25th participant reaches an 18-week follow-up period.
Reqorsa has received orphan drug designation and fast track status from the US Food and Drug Administration (FDA) for use in combination with Tecentriq in ES-SCLC patients whose disease has not progressed after initial standard treatment.
Genprex chief medical officer Mark Berger said: “The Phase I dose escalation portion of the Acclaim-3 study is expected to determine the maximum tolerated dose for the Phase II expansion study.
“The favourable results from our Phase I Acclaim-1 study in non-small cell lung cancer enabled us to shorten the Phase I portion of Acclaim-3.
“This should allow us to complete the Phase I portion of the study during the second half of 2024 and to advance more quickly into the Phase II expansion portion of Acclaim-3 in the second half of 2024.”
"Genprex dosing subjects in trial of combination therapy for small-cell lung cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
https://finance.yahoo.com/news/genprex-dosing-subjects-trial-combination-084204787.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$NRXP NEWS: NRx Pharmaceuticals (Nasdaq: $NRXP) Reports First Quarter 2024 Financial Results & Provides Business Update
2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity
https://ir.nrxpharma.com/2024-05-14-NRx-Pharmaceuticals-Nasdaq-NRXP-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update
#PharmaNews #mentalillness #mentalhealth #mentalhealthawareness #mentalhealthmatters #depression #ketamine #stress #PTSD #bipolar #NRX100 #NRX101
$NCL .4403 +2.53% #TopStock #3DPrinting
$NCL ECO Friendly 3D-Printed Flooring & Wall Panel Products Made Using Recycled Ocean Plastics: Northann Corp. (NYSE: NCL)For more information on $NCL visit: https://icont.ac/4Yp5Z
$GNPX $2.55 +6.69% #BULLISH on #NEWS! Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: https://genprex.com/news/genprex-doses-first-patient-in-acclaim-3-clinical-study-of-reqorsa-immunogene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer/ $GNPX
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: https://t.co/tkW6c8sK89 $GNPX
— Genprex, Inc. (@genprex) May 14, 2024
$NRXP $3.24 +8.36% NRxPharma Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update https://finance.yahoo.com/news/nrx-pharmaceuticals-eyes-first-commercial-135500896.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
@YahooFinance
$META $PALI $DYNT $GBR $MSFT $NFLX $ROKU $SQ $TSLA $NVDA $AAPL $INTC $AMZN $SOFI $GOOGL $AMST $BOF $CSSE $IMCC $GMM $RENB
$AVRW @AvenirWellness Leading LA Plastic Surgeon Recommends Seratopical Skin Care for Superior Anti-Aging Performance: (Stock Symbol: AVRW) - World News Report - EIN Presswire https://world.einnews.com/article/688477296/leading-la-plastic-surgeon-recommends-seratopical-skin-care-for-superior-anti-aging-performance-stock-symbol-avrw via @ein_news
$RENB $1.09 HOD $1.1694 Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance
$NCL .4302 HOD .439 on NEWS Northann Corp. Announces Strategic Partnership with Adornus Cabinetry | NASDAQ https://www.nasdaq.com/press-release/northann-corp.-announces-strategic-partnership-with-adornus-cabinetry-2024-05-14 $GNPX $MSFT
$GNPX $2.40 on NEWS AS GNPX Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer | NASDAQ https://www.nasdaq.com/press-release/genprex-doses-first-patient-in-acclaim-3-clinical-study-of-reqorsar-immunogene
NEWS: $GNPX Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
PR Newswire
Tue, May 14, 2024, 8:31 AM EDT
In this article: GNPX
Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024
Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations
AUSTIN, Texas, May 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).
(PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)
(PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)
"We are excited to take this next step in our fight against lung cancers as we work to advance an innovative therapy that we believe provides hope to patients suffering with ES-SCLC, an especially aggressive form of lung cancer that has extremely limited treatment options," said Ryan Confer, President and Chief Executive Officer at Genprex. "With a median progression free survival (PFS) of 5.2 months, ES-SCLC has a particularly poor prognosis. Additionally, patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. With such limited benefit from current treatments, we believe the combination of REQORSA and Tecentriq can provide a promising new therapeutic option for the treatment of small cell lung cancer."
"The Phase 1 dose escalation portion of the Acclaim-3 study is expected to determine the maximum tolerated dose for the Phase 2 expansion study," stated Mark Berger, M.D., Chief Medical Officer of Genprex. "The favorable results from our Phase 1 Acclaim-1 study in non-small cell lung cancer (NSCLC) enabled us to shorten the Phase 1 portion of Acclaim-3. This should allow us to complete the Phase 1 portion of the study during the second half of 2024 and to advance more quickly into the Phase 2 expansion portion of Acclaim-3 in the second half of 2024. We look forward to providing study updates as we advance this potentially life-saving therapy to benefit patients battling ES-SCLC."
Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. REQORSA contains a plasmid that expresses TUSC2, a tumor suppressor gene protein. Nearly 100% of SCLCs have reduced or no TUSC2 protein expression, and 41% completely lack TUSC2 protein expression. Nonclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq.
About the Acclaim-3 Clinical Trial
The Acclaim-3 clinical trial is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC. The Acclaim-3 clinical trial will enroll patients who did not develop tumor progression after receiving Tecentriq and chemotherapy as standard initial treatment, and who are therefore eligible for maintenance therapy.
The Phase 1 dose escalation portion of the Acclaim-3 clinical study is expected to enroll up to 12 patients at approximately ten U.S. clinical sites to determine the Maximum Tolerated Dose (MTD). If no dose limiting toxicities occur during the Phase 1 study, the highest dose evaluated will be the Recommended Phase 2 Dose. The Phase 2 portion of the study is expected to enroll approximately 50 patients at ten to fifteen U.S. sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. Genprex expects to initiate the Phase 2 expansion study in the second half of 2024.
The primary endpoint of the Phase 2 portion of the trial is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq treatment in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up.
Genprex has received U.S. Food and Drug Administration (FDA) Ophran Drug and Fast Track designations for Reqorsa® Immunogene Therapy, in combination with Genentech, Inc's Tecentriq® in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Additional information about the Acclaim-3 clinical trial can be found by visiting ClinicalTrials.gov.
About Reqorsa® Immunogene Therapy
Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy for NSCLC and SCLC consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid-based molecules in a lipoplex form (Genprex's Oncoprex® Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. In addition, REQORSA disrupts the metabolism of cancer cells by decreasing glycolysis and ATP production in cancer cells with decreased TUSC2.
Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on current therapies for patients with NSCLC, SCLC, and possibly other cancers.
Tecentriq® is a registered trademark of Genentech, Inc.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy, is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
Cision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-doses-first-patient-in-acclaim-3-clinical-study-of-reqorsa-immunogene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302144415.html
SOURCE Genprex, Inc.
$BLIS Update: Company Name Change to NAPC Defense, Inc. (OTCPK: BLIS) and Website to NAPCDefense.com among Business Updates
NAPC Defense has also set visit to Saudi Arabia for presentation of The Corner Shot Weapons System and other NAPC New Arms Technologies
LARGO, Fla., May 13, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc. (formerly known as Treasure & Shipwreck Recovery, Inc.), trading as (OTCPK: BLIS), announces that it has completed the change of name with the State of Nevada and registration with the State of Florida, as well as a new website at www.NAPCDefense.com. It is also finalizing its application with FINRA to effect all additional merger terms announced in the March 27, 2024 press release. NAPC Defense, Inc. owns defense and construction contracting firm Native American Price Constructors, LLC.
More importantly, NAPC is pleased to update its intended large purchase order from a Saudi Arabian company. Field demonstrations for The Corner Shot Weapons Systems will occur in the Kingdom of Saudi Arabia before government, military and other officials during a visit set for the first two weeks of July 2024.
While NAPC maintains a government contracting business, its business includes The Corner Shot Weapons Systems, which is licensed for the United States and the Middle East, as well as brokering of large caliber artillery, mortar, rocket, and smaller caliber munitions sales through allied countries, as approved by the U.S. State Department.
The Saudi Arabia meetings will be for assessment and introduction of the continued contract goal of providing the Corner Shot technology to Saudi Arabia, under a U.S. approved and licensed export of the tactical arms technology. NAPC is a joint venture partner in Saudi Arabia, in the joint venture of NAPC-KSA which is co-owned by NAPC, Kingswood Holding LLC., and AL-SAQR AL–HARR Limited Company. NAPC already has a signed and stamped LOI from a leading Saudi Arabian provider of supply and manufacturing to the Ministry of Defense (MOD).
NAPC management is also in discussion with the Kingdom of Saudi Arabia to provide additional services such as Military Fuzing, and Artillery systems in country, pending expected U.S. State Department approval. NAPC expects significant discussions to expand during the official visit in this arena.
In expanding its arms related business, NAPC is also developing a rifle and suppressor line for domestic government and international sales. NAPC expects to release more information on these product lines in the short term as prototypes are being completed for testing.
NAPC will also be participating in a number of law enforcement conventions to display The Corner Shot and other product lines. Such conventions and shows include Florida Police Chiefs Assoc. 72nd Annual Summer Training Conference & Exposition in Pointe Vedra Beach, FL – June 7th – 12th 2024 (Booth #139) and 38th Annual NJ Police Security Expo. in Atlantic City, NJ – June 24th – 26th (Booth #1037).
Finally, NAPC Defense is active in brokering of munitions and military hardware already produced and in inventory at various locations worldwide. NAPC is currently brokering a number of different munitions and military hardware items that are of interest to Allied and NATO forces for the Ukraine and the Middle East, which also require U.S. State Department approval. Any successful transaction would add significantly to NAPC revenues and profits. The inventory of these items, if sold at currently offered fair value, totals over (U.S.) $2.5 billion.
NAPC will update the status of its corporate actions, weapons development, and shows in future releases.
About NAPC Defense, Inc.
NAPC Defense, Inc. (https://www.napcdefense.com/) is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell Corner Shot USA weapons systems, in addition to brokering arms and munitions throughout the world all with US State Department approval. Additional smaller weapons platforms and related products are in development.
Please go to https://www.napcdefense.com/investor-relations for Investor Relation Page.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC. (the "Company") related thereto contain, or may contain, among other things, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including any other statements of non-historical information. These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as "guidance," "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "ultimately" or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO
kwest@napconstructors.com
754-242-6272
https://www.globenewswire.com/newsroom/ti?nf=OTExNTk5OCM2MjQ3NjExIzIyNjE1MDY=
https://ml.globenewswire.com/media/ZjM4YWY1M2QtNzdhMy00Nzk4LTkxNzYtYjVkZGZmN2M2YjMwLTEyNzMwNTY=/tiny/Treasure-Shipwreck-Recovery-In.png Source: Treasure & Shipwreck Recovery, Inc.
$NCL - #NEWS (NYSEAM: NCL @Northann_Corp Announces Strategic Partnership with Adornus Cabinetry https://finance.yahoo.com/news/northann-corp-announces-strategic-partnership-120000091.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance #partnership #3Dprinting #BreakingNews
$BLIS - BUY OPINION 88% STRONG BUY https://www.barchart.com/stocks/quotes/BLIS/opinion
@NAPCDefense #bullish #OTCMarkets
$GNPX $2.36 +1.72 HOD $2.59 Genprex's Gene Therapy: Potential Breakthrough For Diabetes And Lung Cancer https://seekingalpha.com/article/4585494-genprex-gene-therapy-potential-breakthrough-diabetes-lung-cancer $GME $RENB $NRXP $AMC $BMY $JNJ $TLRY
$BLIS News: Company Name Change to NAPC Defense, Inc. (OTCPK: BLIS) and Website to NAPCDefense.com among Business Updates
NAPC Defense has also set visit to Saudi Arabia for presentation of The Corner Shot Weapons System and other NAPC New Arms Technologies
https://www.globenewswire.com/news-release/2024/05/13/2880419/0/en/Company-Name-Change-to-NAPC-Defense-Inc-OTCPK-BLIS-and-Website-to-NAPCDefense-com-among-Business-Updates.html
$BLIS Daily Chart 5 day change +23.68% 1-month change 72.34% 6 months +202.52% YTD 637.72%
$DIS $DISH $GOOG $HD $INTC $IWM $JPM $LK $LOW $LULU $LYFT $MA $MSFT $NVDA $NFLX $PINS $QQQ $RH $ROKU $SNAP $SPY $TLT $T $TSLA $TVIX $UWT $UVXY $GME $AMC $RENB
https://www.tradingview.com/symbols/OTC-BLIS/
$NCL NYSE:NCL pioneering sustainable innovation in the home improvement industry, delivering cutting-edge 3D printed flooring & wall panels that redefine modern living gaining recognition with products receiving top honors at industry events like #TISE2024 https://axecapitalusa.com/ncl/
$NRXP Attending the EF Hutton Annual Global Conference this Wednesday at The Plaza Hotel in NYC! Read More - https://ir.nrxpharma.com/2024-05-08-NRx-Pharmaceuticals,-Inc-NASDAQ-NRXP-to-Participate-in-the-EF-Hutton-Annual-Global-Conference-on-May-15,-2024
A reminder that NRx Pharmaceuticals will participate in the EF Hutton Annual Global Conference, taking place this Wednesday, May 15, 2024, at The Plaza Hotel in New York City.
— NRx Pharmaceuticals (@NRxPharma) May 13, 2024
Read More - https://t.co/LfEtS29gsl#PharmaNews #ketamine #PTSD #bipolar #NRX100 #NRX101 $NRXP
$RENB RENOVAROCUBE TO ACQUIRE 100% OWNERSHIP OF CYCLOMICSRenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics advancing state-of-the-art technologies in cancer diagnostics and treatment. https://www.cyclomics.com/ #Cancer #acquistion #research #cyclonomics
$GNPX $2.59 HOD on NEWS! Genprex Inc Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors https://www.genprex.com/news/genprex-announces-the-appointment-of-jose-a-moreno-toscano-as-chairman-of-the-board-of-directors/ #mondayNews #Radar @nasdaq $BMY $NPRX $RENB $GME #news
$GNPX should be on your radar! Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Advancing novel gene therapies for patients afflicted with cancer or diabetes. Our lead drug candidate, REQORSA® Immunogene Therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, target and kill cancer cells, and stimulate the natural immune responses against cancer. https://www.genprex.com/technology/reqorsa/
$AVRW Avenir Wellness Solutions markets the Sera Labs Inc. Seratopical Wellness skin care line including the advanced new DNA Complex that work from the inside out to deliver powerful and long lasting anti-aging results. https://seralabshealth.com/
$IVDN Low Float of 16 million is on track for a record sales and revenue growth year in 2024, as detailed in official company news below. IVDN management is making steady progress to grow market share and also protect the very valuable patent rights of its unique Insultex product line which is the only evacuated cell insulation on the market with energy saving performance that no competitor can match.
IVDN is now starting to see accelerating sales success as word is spreading about Insultex House Wrap as described on the dedicated website at http://www.insultexhousewrap.com. Add to this advantage, the fact that the IVDN product meets or exceeds new building codes going into effect this year requiring continuous insulation while competitors are failing this critical criteria. www.InsultexHouseWrap.com
Innovative Designs Vendor Growth
https://finance.yahoo.com/news/innovative-designs-vendor-growth-174255528.html
World International Patent Organization (WIPO) Application Accepted on Superior Insulation Advancement to Maximize Global Marketing Opportunities for Innovative Designs, Inc.
Dec. 27, 2023
https://www.newmediawire.com/news/world-international-patent-organization-wipo-application-accepted-on-superior-insulation-advancement-to-maximize-global-marketing-opportunities-for-innovative-designs-inc-7071640
$NRXP $2.98 +1.71% HOD $3.04 @NRxPharma
NRx Pharmaceuticals Sets Sights on Debut Commercial Revenue in 2024, Unveils Innovative Advances in Bi-Annual Progress Report: (Nasdaq: NRXP) https://www.kxan.com/business/press-releases/ein-presswire/709692023/nrx-pharmaceuticals-eyes-first-commercial-revenue-in-2024-announces-breakthroughs-in-bi-annual-milestones-nasdaq-nrxp/
$RENB - Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection - NVIDIA (NASDAQ:NVDA)
https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer- #Benzinga #Healthcare #Biopharma #Cancersucks $NVDA #AI #Computing #Power
$RENB Up premarket $1.26 +5.00% #Cancer #acquistion #research #cyclonomics
$RENB RENOVAROCUBE TO ACQUIRE 100% OWNERSHIP OF CYCLOMICSRenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics advancing state-of-the-art technologies in cancer diagnostics and treatment. https://www.cyclomics.com/ $NRXP
$RENB Buy Opinion. Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection #Bullish https://www.benzinga.com/partner/biotech/24/05/38641138/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer-
$ACGX Interview out: #PeopleVine great interview w/ our founder Jordan Gilman https://lnns.co/duCxsyg0NXP https://peoplevine.com #LuxuryHospitality #UKExpansion #PrivateMembership #GuestExperience #MembershipClubs #MemberPayments #GlobalProfile #CRM $ACGX
$IVDN According to Grand View Research, the global insulation market size was estimated at USD $52.18 billion in 2018 and is expected to expand at a CAGR of 5.7% going forward. Increasing consumer awareness regarding energy conservation is estimated to propel growth.
$NRXP $2.81 HOD $2.87 NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales https://prn.to/4baoVcG $RENB $BMY
$NCL Invest in @Northann_Corp to be part of a journey towards a greener, more technologically advanced future. Join NCL in shaping tomorrow, sustainably & inclusively building a world where style meets sustainability & innovation drives success. https://axecapitalusa.com/ncl/ $INTC
$RENB Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils Flamingo, a potentially groundbreaking multi-cancer detection model https://finance.yahoo.com/news/transforming-cancer-detection-renovarocube-introduces-150000564.html $TWST
$NRXP @NRxPharma Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update https://finance.yahoo.com/news/nrx-pharmaceuticals-eyes-first-commercial-135500896.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via
@YahooFinance
$META $PALI $DYNT $GBR $MSFT $NFLX $ROKU $SQ $TSLA $NVDA $AAPL $INTC $AMZN $SOFI $GOOGL $AMST $BOF $CSSE $IMCC $GMM $RENB
Do you Need Investor Relations Services- FrontPageStocks handles your company needs #OTC Nasdaq #NYSE #Pinks FPS offers the complete concierge service to clients. Referrals upon request. https://lnkd.in/exnrixwJ
$AGCX Alliance Creative Group in 2024 applying resources towards diversified classifications of real estate. Low Float of 2,424,023 #ACGX
Pink Current Info- The Company Profile data was verified by the issuer within the previous 6 months.
Verified Profile 02/2024
$ACGX Update: The Wayne & Devon property is listed on LoopNet - 7.97% Cap rate! Check it out and share it with all potential buyers. #OTCmarkets #RealEstate #Investments #ACGX https://t.co/AMyyDJbR3S
— $ACGX (@ACGpaul) April 29, 2024
$NRXP Huge article out! NRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone Update https://finance.yahoo.com/news/nrx-pharmaceuticals-eyes-first-commercial-135500896.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$RENB RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership #cancer #diagnostics @Nasdaq
https://ir.renovarogroup.com/news/news-details/2024/RenovaroCube-to-Acquire-100-Ownership-of-Cyclomics-Reinforcing-Cutting-Edge-Cancer-Diagnostics-Partnership/default.aspx
$NCL Prestigious Awards Granted for Eco-Friendly 3D-Printed Flooring & Wall Panel Products: Northann Corp. NYSE: NCL https://www.einpresswire.com/article/708225478/prestigious-awards-granted-for-eco-friendly-3d-printed-flooring-wall-panel-products-northann-corp-nyse-ncl via @ein_news
$IVDN -Significant improvements in energy efficiency measures, such as Insultex House Wrap® can provide, have never been more important. Superior insulation performance, for heating or cooling, directly translates into lower demand from energy suppliers. The pay-off is lower energy bills and also a reduction of greenhouse gas emissions that contribute to the global climate change crisis which has become such a major concern today.
Patent update -(OTCQB: IVDN) is continuing to develop and protect its proprietary advanced insulation technologies. We are pleased to announce the filing and acceptance of an International Patent Application with the World International Patent Organization (WIPO) https://finance.yahoo.com/news/world-international-patent-organization-wipo-173700350.html
$NRXP NEWS: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-123000426.html
$AVRW @SeralabsHealth NUTRI-STRIPS are the more effective alternative to traditional supplements. Sales are starting to build up. Sales building as Demand Grows. #OTCQB https://stkt.co/lPj79qxU
$NCL .42 +2.50% Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product Wins Multiple Prestigious Awards in 2024
Thu, May 2, 2024, 8:00 AM EDT
In This Article: NCL - Northann Corp.
ELK GROVE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL), a leader in innovative sustainable solutions, today announced that its Blue11-Ocean Plastic Flooring and Wall Panels Product has been recognized this year with industry awards for outstanding design, commitment to sustainability, and impeccable craftsmanship.
These awards include:
American Good Design Award 2024
French Design Award 2024
IDA Design Awards 2024
New York Product Design Awards
Green Product Award
Best Surfaces in TISE 2024
"We are truly honored to receive these prestigious awards, which underscore our commitment to creating products that are not only visually captivating but also environmentally conscious," remarked Northann Corp. CEO Lin Li. "This recognition fuels our passion to continue delivering innovative and sustainable solutions that resonate with our customers and contribute positively to the environment.
“Northann Corp.'s Blue11-Ocean Plastic Flooring and Wall Panels Product stands as a shining example of our company's enduring pursuit of excellence and sustainability.”
To learn more about this award-winning product and Northann Corp.'s comprehensive range of sustainable solutions, please visit www.northann.com and www.benchwick.com.
About Northann Corp.
Northann specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The Company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers its 3D printing ecosystem as an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The Company aims to redefine the essence of modern flooring and wall panels by offering stylish, durable, and ecologically conscious solutions.
For more information about Northann, please visit www.northann.com.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
Investor Relations
Northann Corp.
Email: ir@northann.com
Phone: +1 (916) 573-3803
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor New York, NY, 10036
Office: (646) 893-5835 x2
Email: info@skylineccg.com
$NRXP -Of the thousands of drugs approved by FDA, only 544 have been designated as “Breakthrough Therapy.” NRX-101 is the first Breakthrough Therapy for Suicidal Depression https://axecapitalusa.com/nrxp/
$RENB Launch of Groundbreaking AI Cancer Detection Platform Flamingo; Powered by Nvidia; Acquiring Cyclomics: NASDAQ: RENB https://www.einpresswire.com/article/707739804/launch-of-groundbreaking-ai-cancer-detection-platform-flamingo-powered-by-nvidia-acquiring-cyclomics-nasdaq-renb via @ein_news $NRXP $BMY
$NCL .446 +8.84% Top Reasons to Have NCL on Your Radar
$NCL The global 3D printing market is on an upward trajectory, projected to soar from USD 18.33 Billion in 2022 to a staggering USD 105.99 Billion by 2030, with a robust CAGR of 24.9% during the forecast period. https://axecapitalusa.com/ncl/
$AVRW CEO Nancy Duitch stated, "Avenir Wellness Solutions has never been in a better position to capitalize on the high intrinsic value of our unique and proprietary skin care formulations. With 15 patents under our control, the highly positive reviews Seratopical DNA Complex is receiving, and more new products in development, 2024 is set up to be a growth year for the Company. We look forward to keeping our shareholders informed of our progress, developments and milestones as we move forward."
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$NRXP Based on the announcement today of its safety finding, NRx plans to seek Accelerated Approval of NRX-101 for treatment of bipolar depression in patients at risk for akathisia who are at highest risk of suicide. https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-final-clinical-trial-results-superior-safety-combined-with-similar-efficacy-in-the-trial-of-nrx-101-compared-to-lurasidone-in-suicidal-bipolar-depression-302136430.html
$NCL -Northann Corp. price alert $0.44 (+4.82%)
@Northann_Corp
Enters Strategic Relationship with Rexil Group of Companies Netherlands to Promote Sustainable Technology and Products https://seekingalpha.com/pr/19698202-northann-corp-enters-strategic-relationship-rexil-group-of-companies-netherlands-to-promote?source=tweet
#NorthannCorp #Sustainability #Innovation
Followers
|
118
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
37854
|
Created
|
07/31/17
|
Type
|
Free
|
Moderator jedijazz | |||
Assistants ProfitScout paytheask budfoxfun FrontPageStocks |
FRONT PAGE STOCKS BOARD ![yes yes](https://investorshub.advfn.com/ckeditor/plugins/smiley/images/thumbs_up.png)
Company Profiles:
Shareholder-Friendly Moves Returns 4 Million Shares of Preferred Stock to Company, Plus Equity Partnership with Coastal Spritz Brand and New Business Plans Focused on Real…
Advanced Thin Film Solar Power Technology Used in Aerospace and by NASA, Industrial/Commercial Construction and Many Consumer Goods; Reaching Record Power Generation Milestones: Ascent Solar…
Increasingly Positive Fundamentals Reported for Marketerof Best Performing Skin Care Line with Endorsements by Nicole Kidman and Top Plastic Surgeon: Avenir Wellness Solutions, Inc. (Stock…
New European Supply Chain Center to Enhance Global Growth of Interconnected Products Needed in a Wide Range of Industries: CCSC Technology International Holdings Limited (Nasdaq:…
Clinical Trials Commenced for Promising Acclaim-3 Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: Genprex, Inc. (NASDAQ: GNPX)GNPX in combination…
Expanding Prospects Ahead for Nicaragua Imported Handmade Premium Cigar Business Backed by Strong Family History and Experience: Green Leaf Innovations, Inc (Stock Symbol: GRLF).For additional…
Cross-Licensing Agreement with I4F to Expand Business Strategies for 3D Printed Ecosystem Flooring and Wall Pannel Products Made with Recycled Ocean Plastics: Northann Corp (NYSE:…
Trial Endpoint Reached for First Suicidal Bipolar Depression, Chronic Pain and PTSD Drug; Agreement with Partners Can Provide up to $329 Million and Royalties: NRx…
Trailblazing AI Driven Early Cancer Diagnostics and Therapeutics for Detection with Nvidia Super Computing Power; Acquiring100% Ownership of Cyclomics; Renovaro Inc. (Nasdaq: RENB)$RENB is Working…
AI Education Provider Plans for New Facilities and Enters Agreement with Top 500 Company in China to Establish Life Sciences Conglomerate in Toronto: Visionary Holdings…
Establish Life Sciences Conglomerate in Toronto: Visionary Holdings…
We believe in building long lasting relationships as noted by our vast amount of real, contactable clients hat span over 2 decades!
This helps individual investors to investigate compelling investments.
We are a link between small public companies and the investing public. The company’s plans, profiles and information are written with the individual investor in mind.
Our goal is to explain the complex, reduce the jargon, and provide a clear and engaging story of each company’s strategy and growth potential.
Bringing you this information requires our staff to work closely with each featured company, as we are small cap stock investors ourselves.
We want what you want – an understanding of what the company does, how they make money and how they intend to grow with frequent company updates.
Small cap investing is unlike buying shares of an S&P 500 company. It is generally a longer term commitment that generates an emotional link with the company.
An understanding of opportunity and the company plan generate the interest. Continued updates and information provide the basis for a satisfied and supportive investor base.
Here at Front Page Stocks, we understand that relationship ultimately closing the gap between investor and company.
We promise to present to you engaging, real companies with real products and services. We hope they will captivate and excite you in return.
Posts Today
|
1
|
Posts (Total)
|
37854
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |